# A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Source: https://onco.cc/trials/nct04879329/  
OnCo record `nct04879329` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Disitamab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Seagen, a wholly owned subsidiary of Pfizer, now recruiting.

## Summary

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 is a phase 2 interventional study registered as NCT04879329 by Seagen, a wholly owned subsidiary of Pfizer, with 372 participants planned, started 2022-05-03 and due to reach its primary completion in 2026-12-11. Interventions recorded: disitamab vedotin and pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04879329
- Phase: 2
- Setting: A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Enrolled: 372

## Sources

- ClinicalTrials.gov NCT04879329: https://clinicaltrials.gov/study/NCT04879329

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04879329.json